Companies › Tortugas Neuroscience
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Other; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TRTL-913 | – | Phase 2 | Tinnitus | Aug 2027 |
| TRTL-729 | – | Phase 1 | Healthy Volunteers | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07811063 | TRTL-729 | Phase 1 | Healthy Volunteers | Other | Jan 2027 |
| NCT07777549 | TRTL-913 | Phase 2 | Tinnitus | Other | Aug 2027 |
No annotated target.
–
Sirnaomics Healx Skingenix Sensory Cloud Shanghai Huilun Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.